Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs

被引:0
作者
Jehun Song
Seongmin Kang
Seung Won Choi
Kwang Won Seo
Sunggun Lee
Min Wook So
Doo-Ho Lim
机构
[1] University of Ulsan College of Medicine,Division of Rheumatology, Department of Internal Medicine, Ulsan University Hospital
[2] University of Ulsan College of Medicine,Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ulsan University Hospital
[3] Inje University College of Medicine,Division of Rheumatology, Department of Internal Medicine, Haeundae Paik Hospital
[4] Pusan National University Yangsan Hospital,Division of Rheumatology, Department of Internal Medicine
来源
Rheumatology International | 2020年 / 40卷
关键词
Coronavirus; COVID-19; Pneumonia; Rheumatoid arthritis; Disease-modifying antirheumatic drugs;
D O I
暂无
中图分类号
学科分类号
摘要
In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
引用
收藏
页码:991 / 995
页数:4
相关论文
共 69 条
[1]  
Listing J(2012)The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment Rheumatology 52 53-61
[2]  
Gerhold K(2011)Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors Rheumatol Int 31 1409-1417
[3]  
Zink A(2009)Identification of new risk factors for pneumonia: population-based case-control study Br J Gen Pract 59 e329-338
[4]  
Gasparyan AY(2012)Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study BMC Musculoskelet Disord 13 158-9208
[5]  
Ayvazyan L(2000)T cell homeostasis in patients with rheumatoid arthritis Proc Natl Acad Sci USA 97 9203-330
[6]  
Blackmore H(2017)Infections in rheumatoid arthritis Curr Opin Rheumatol 29 323-1518
[7]  
Kitas GD(2017)BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs Rheumatology (Oxford) 56 2257-767
[8]  
Vinogradova Y(2015)Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial Lancet (London, England) 385 1511-309
[9]  
Hippisley-Cox J(2019)The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis Crit Care (London, England) 23 99-68
[10]  
Coupland C(2018)Corticosteroid therapy for critically ill patients with middle east respiratory syndrome Am J Respir Crit Care Med 197 757-177